Cargando…

Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement

Anaplastic large cell lymphomas (ALCL) are mature T-cell neoplasms, approximately half of which harbor rearrangements of the ALK gene that confer a good prognosis. Recent studies have demonstrated that a significant proportion of ALK-negative ALCLs demonstrate rearrangements of the IRF4/DUSP22 locus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magaki, Shino, Satyadev, Radha, Chen, Zesheng, Yung, Kathryn S., Vinters, Harry V., Kinney, Marsha C., Said, Jonathan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752532/ https://www.ncbi.nlm.nih.gov/pubmed/34791573 http://dx.doi.org/10.1007/s10014-021-00415-0

Ejemplares similares

Primary cutaneous anaplastic large‐cell lymphoma with DUSP22‐IRF4 rearrangement following insect bites
por: Zhang, Yaping, et al.
Publicado: (2021)

DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma
por: Qiu, Lianqun, et al.
Publicado: (2022)

DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome
por: Savage, Kerry J., et al.
Publicado: (2022)

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
por: Sibon, David, et al.
Publicado: (2022)

Evaluating when (and how) hypertension may be ‘good for your brain’
por: Magaki, Shino D, et al.
Publicado: (2023)

Charcot–Bouchard aneurysms revisited: clinicopathologic correlations
por: Magaki, Shino, et al.
Publicado: (2021)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

Brain biopsy in neurologic decline of unknown etiology
por: Magaki, Shino, et al.
Publicado: (2014)

Illustrated Neuropathologic Diagnosis of Alzheimer’s Disease
por: Doher, Nicholas, et al.
Publicado: (2023)

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
por: Hayashi, Nobuyoshi, et al.
Publicado: (2017)

Arteriolar neuropathology in cerebral microvascular disease
por: Fang, Chuo, et al.
Publicado: (2023)

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene
por: van der Krogt, Jo-Anne, et al.
Publicado: (2017)

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
por: Lee, Jeeyun, et al.
Publicado: (2015)

Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung
por: Shi, Mingxia, et al.
Publicado: (2018)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
por: Shigeta, Naoko, et al.
Publicado: (2023)

Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Rearrangement Presenting as Carcinoma of Unknown Primary Site: Recognition and Treatment Implications
por: Hainsworth, John D., et al.
Publicado: (2016)

Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation‐related human papillary thyroid carcinoma after the Chernobyl accident
por: Arndt, Annette, et al.
Publicado: (2018)

Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review
por: Watanabe, Junko, et al.
Publicado: (2018)

Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
por: Zhou, Xiaoyun, et al.
Publicado: (2019)

Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma
por: Verran, Julian, et al.
Publicado: (2022)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects
por: Tang, Zhenya, et al.
Publicado: (2019)

Anaplastic lymphoma kinase (ALK) rearrangement in adult renal cell carcinoma with lung metastasis: a case report and literature review
por: Zhou, Shengyu, et al.
Publicado: (2020)

Anaplastic Lymphoma Kinase (ALK)-Rearranged Lung Cancer That Showed Exclusively Scattered Isolated Cells Devoid of Mucin Production in Cytology
por: Okazaki, Tsuyoshi, et al.
Publicado: (2023)

Primary Central Nervous System ALK Positive Anaplastic Large Cell Lymphoma with Predominantly Leptomeningeal Involvement in an Adult
por: Park, Jae Sung, et al.
Publicado: (2013)

Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report
por: Yuan, Cai, et al.
Publicado: (2017)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement
por: Rigaud, Charlotte, et al.
Publicado: (2022)

A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
por: Kashima, Jumpei, et al.
Publicado: (2016)

Pathobiology of ALK-negative anaplastic large cell lymphoma
por: Pileri, Stefano A., et al.
Publicado: (2011)

ALK-positive anaplastic large cell lymphoma in adults
por: Gromowsky, Matthew J, et al.
Publicado: (2023)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer
por: Tan, Chye Ling, et al.
Publicado: (2016)

Primary central nervous system ALK-positive anaplastic large cell lymphoma in an adult: A rare case report
por: Dong, Xiaoqin, et al.
Publicado: (2016)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nmn1qk3gqljicdcmcdb3bfq79s